The Pharma Letter

New EC approval for Dupixent in CSU

The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous ...

Sanofi: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly ...
Scientific Research Publishing

Regenerative and Stem-Cell Based Approaches for Rhinitis: From Pathophysiology to Translational Models ()

Skin regeneration: Though less directly tied to rhinitis, external nasal defects from surgery or chronic inflammation can be ...

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...

Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

Atopic Dermatitis Drugs Market to Reach $29.43 Billion by 2032, Driven by Rising Disease Prevalence & Strong Therapeutic Innovation | SNS Insider

According to research by SNS Insider, the U.S. Atopic Dermatitis Drugs Market is projected to grow at a CAGR of 8.57%, supported by high disease burden, strong R&D pipelines, and rapid adoption of ...